Marine Desjonqueres-Fouillet

Groupement Hospitalier Est
Bron, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Early and transient expansion of TCR Vβ21.3+ T cells in children with MIS-C: Clinical and longitudinal immunological characterization.

Early and transient expansion of TCR Vβ21.3+ T cells in children with MIS-C: Clinical and longitudinal immunological characterization.

Journal: Joint bone spine

Published: March 15, 2026

Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases.

Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases.

Journal: EBioMedicine

Published: October 07, 2025

Trametinib for multiple non-ossifying fibromas due to KRAS mosaic mutations: two case reports.

Trametinib for multiple non-ossifying fibromas due to KRAS mosaic mutations: two case reports.

Journal: Communications medicine

Published: May 19, 2025

Clinical predictors of remission in systemic juvenile idiopathic arthritis/Still's disease: insight from real-life data and the potential relevance of the 'window of opportunity'.

Clinical predictors of remission in systemic juvenile idiopathic arthritis/Still's disease: insight from real-life data and the potential relevance of the 'window of opportunity'.

Journal: Clinical and experimental rheumatology

Published: January 16, 2025

Evaluation of the benefits of adapted physical activity in children and adolescents with osteogenesis imperfecta: the MOVE-OI trial.

Evaluation of the benefits of adapted physical activity in children and adolescents with osteogenesis imperfecta: the MOVE-OI trial.

Journal: Orphanet journal of rare diseases

Published: November 27, 2024

Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort.

Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort.

Journal: Rheumatology (Oxford, England)

Published: November 11, 2024

Sustained remission after bispecific antibody anti-IL-1β/anti-IL-18 therapy in a severe childhood Still's disease with recurrent macrophage activation syndrome.

Sustained remission after bispecific antibody anti-IL-1β/anti-IL-18 therapy in a severe childhood Still's disease with recurrent macrophage activation syndrome.

Journal: Joint bone spine

Published: November 03, 2024

JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.

JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.

Journal: Journal of autoimmunity

Published: January 07, 2024

The Spectrum of Still's Disease: A Comparative Analysis of Phenotypic Forms in a Cohort of 238 Patients.

The Spectrum of Still's Disease: A Comparative Analysis of Phenotypic Forms in a Cohort of 238 Patients.

Journal: Journal of clinical medicine

Published: October 10, 2022

Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.

Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.

Journal: Journal of clinical medicine

Published: November 30, 2021

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.

Journal: Annals of the rheumatic diseases

Published: February 01, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026